Pablo Canales-Herrerias
@pabloimmune
Postdoc at @Mehandrulab & Cerutti labs at @IcahnMountSinai. Mucosal #Bcell responses & #HIV. Previously @institutpasteur @JohnsHopkins. @pabloimmune.bsky.social
ID: 69381968
http://linkedin.com/in/pablo-immune 27-08-2009 19:35:36
431 Tweet
606 Followers
1,1K Following
Amazing 🗞️ paper abt MoAction one of the most 🔐 precision biologic in #UlcerativeColitis treatment since 2015 🗝️ 🔓 #Vedolizumab 👉 Anti-α4β7 therapy results in a decrease ⬇️ of #naïve B & T cells in🎯 intestinal mucosa of #UC patients Science Immunology doi.org/10.1126/sciimm…
Check out our new work in Science Immunology! Gut-associated lymphoid tissue targeting in IBD. New insights into vedolizumab MOA Icahn School of Medicine at Mount Sinai Lipschultz Precision Immunology Institute Mount Sinai Division of Gastroenterology
How does vedolizumab work in ulcerative colitis patients? Researchers in a new Science Immunology study say the drug targets gut-associated lymphoid tissue. Learn more: scim.ag/6Im
How does vedolizumab work in ulcerative colitis patients? Researchers in a new Science Immunology study say the drug targets gut-associated lymphoid tissue. Learn more: scim.ag/6KJ
Thank you for the highlight Science Magazine! 🔦 science.org/doi/10.1126/sc… 📄science.org/doi/10.1126/sc…
Gut-associated lymphoid tissue may shape drugs' efficacy. .Pablo Canales-Herrerias & colleagues describe targeting of gut-associated lymphoid tissue as a novel mode of action of anti-α4β7 therapy in IBD via Science Immunology: science.org/doi/10.1126/sc…
Out now 🚨 in Gastroenterology is your latest update on selective IL-23p19 inhibition in IBD! Amongst other topics featuring discussion of pathogenesis, PD/PK, efficacy, safety, positioning, and more! Together with Jean-Frederic Colombel Mehandru Lab @MountSinai & Ryan Ungaro MD MS gastrojournal.org/article/S0016-…
Front-line drug for ulcerative colitis found to have additional mechanism of action that until now remained elusive (Vdz) medicalxpress.com/news/2024-07-f… via Medical Xpress
Front-line drug for ulcerative colitis found to have additional mechanism of action that until now remained elusive medicalxpress.com/news/2024-07-f… via Medical Xpress
We are looking for post-docs. Interested in early life human immunity and bioinformatics? We have a number of really interesting projects. Spread the word and please apply! Yale Pediatrics Yale Department of Immunobiology
According to a Mount Sinai study, Vedolizumab, a mainstay drug for managing ulcerative colitis, appears to work by targeting gut-associated lymphoid tissue. Read more: mshs.co/3zacgc0 Mount Sinai Department of Medicine Mount Sinai Division of Gastroenterology #IBD
Check this out from @francescacossa1 and Mehandru Lab @MountSinai 🔥🔥 Lipschultz Precision Immunology Institute Mount Sinai Division of Gastroenterology Science Immunology 👇
Intestinal germinal center B cell reduction in HIV-1 infection is linked to reduced IgA+ plasma cells and systemic inflammation Science Immunology @francescacossa1 saurabh mehandru science.org/doi/10.1126/sc…
Please RT 🙏!📢My lab at Universitat de Barcelona is seeking a highly motivated postdoc to lead an exciting new public-private collaborative project (UB, CRG, CSIC, OrikineBio) aimed at testing a potentially game-changing therapy for IBD. If interested, please contact me at [email protected].
